Moleculin Biotech Inc. (MBRX), a clinical-stage pharmaceutical company, on Thursday presented preclinical data for Annamycin in treating pancreatic cancer, at the 2026 annual meeting of the American Association for Cancer Research (AACR).
Annamycin (L-ANN), the company's lead drug candidate, is a novel, non-cardiotoxic anthracycline that showed significant tumor growth inhibition in pancreatic ductal carcinoma (PDAC) models.
Preclinical testing yielded meaningful survival benefits in metastatic models, with a median survival of over 60% compared to control treatments. This indicated enhanced tumor penetration, with higher accumulation of the drug observed in pancreatic tumors. Annamycin was effective both as a monotherapy, and in combination with immune checkpoint and KRAS inhibitors.
Moleculin is currently evaluating Annamycin in combination with cytarabine (AnnAraC) in the Phase 2/3 MIRACLE trial for the treatment of relapsed/refractory acute myeloid leukemia (AML).
MBRX closed Thursday at $2.54, up 1.60%. In the overnight market, shares are trading at $2.59, up 1.97%.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.